Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech announced ahead-of-schedule enrollment completion for its Phase 2 DURIPANC trial (Ampligen + Imfinzi in m | Jun 1, 2026 |
| OPTX | PRESS-RELEASE | bullish | 6/10 | Syntec Optics (OPTX) announced its preliminary inclusion in the Russell 3000 Index, effective June 26, 2026. This is exp | Jun 1, 2026 |
| PRZO | PRESS-RELEASE | neutral | 5/10 | ParaZero Technologies announced its first order from a U.S.-based Tier-1 defense corporation for DefendAir Net Pods, mar | Jun 1, 2026 |
| UNIT | PRESS-RELEASE | bullish | 7/10 | Uniti Group's bankruptcy-remote subsidiary, Kinetic ABS Issuer LLC, is issuing ~$1.14 billion of secured fiber network r | Jun 1, 2026 |
| PYPD | PRESS-RELEASE | bullish | 7/10 | PolyPid completed its rolling NDA submission to the FDA for D-PLEX100 to prevent surgical site infections in colorectal | Jun 1, 2026 |
| FTRK | PRESS-RELEASE | neutral | 3/10 | Fast Track Group's subsidiary FTE was engaged by Dream Cruises for a three-part celebrity partnership campaign to celebr | Jun 1, 2026 |
| RZLV | PRESS-RELEASE | bullish | 7/10 | Rezolve AI reported Q1 2026 revenue of ~$60M, exceeding its entire FY2025 revenue of $46.8M, and reaffirmed FY26 guidanc | Jun 1, 2026 |
| RMCF | PRESS-RELEASE | bearish | 6/10 | Rocky Mountain Chocolate Factory reported a weak Q4 FY2026 with total revenue of $6.8M, down 24% YoY from $8.9M, driven | Jun 1, 2026 |
| PLXS | PRESS-RELEASE | neutral | 2/10 | Plexus issued its Fiscal 2025 Sustainability Report, shifting from intensity-based to absolute emissions reduction targe | Jun 1, 2026 |
| DFNS | PRESS-RELEASE | neutral | 2/10 | T3 Defense Inc. announced its participation in a virtual investor conference (Noble Capital Markets, June 3-4, 2026). Th | Jun 1, 2026 |
| FATE | PRESS-RELEASE | bullish | 6/10 | Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid | Jun 1, 2026 |
| VATE | PRESS-RELEASE | bullish | 7/10 | INNOVATE Corp. announced the sale of a controlling 75% stake in its HC2 Broadcasting subsidiary to CONX CORP., coupled w | Jun 1, 2026 |
| IRON | PRESS-RELEASE | neutral | 4/10 | Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked p | Jun 1, 2026 |
| COSM | PRESS-RELEASE | neutral | 3/10 | Cosmos Health announced the planned launch of its C-Scrub antimicrobial wash in a veterinary formulation following succe | Jun 1, 2026 |
| ODV | PRESS-RELEASE | mixed | 6/10 | Osisko Development closed an additional $75M in convertible notes (full exercise of initial purchasers' option + $50M pr | Jun 1, 2026 |
| CLRB | PRESS-RELEASE | bullish | 7/10 | Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in post-BTKi Waldenström m | Jun 1, 2026 |
| ASML | PRESS-RELEASE | neutral | 2/10 | ASML disclosed share repurchase transactions under its ongoing buyback program. The press release provides no financial | Jun 1, 2026 |
| JSPR | PRESS-RELEASE | bearish | 8/10 | Jasper Therapeutics announced a comprehensive review of strategic alternatives, including a potential sale, licensing, m | Jun 1, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, sho | Jun 1, 2026 |
| VERX | PRESS-RELEASE | bearish | 6/10 | Vertex Inc. reported Q1 2026 EPS of $0.17, missing the consensus estimate of $0.19 by 10.6%, while revenue of $202.2M ma | Jun 1, 2026 |
| GASS | PRESS-RELEASE | neutral | 1/10 | STEALTHGAS INC. announced it will report its Q1 2026 results on June 5, 2026. | Jun 1, 2026 |
| NXTC | PRESS-RELEASE | bullish | 7/10 | NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO 2026, showing a 55% | Jun 1, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings (ELAB) announced a non-binding LOI to acquire a 76% controlling interest in a privately held precision mac | Jun 1, 2026 |
| ATHS | PRESS-RELEASE | neutral | 3/10 | Athene Holding Ltd. appointed Matthew Michelini as President, effective July 1, 2026, signaling continuity in leadership | Jun 1, 2026 |
| CGTX | PRESS-RELEASE | neutral | 2/10 | Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wa | Jun 1, 2026 |
| SLG | PRESS-RELEASE | bullish | 6/10 | SL Green Realty Corp. announced the sale of 10 East 53rd Street for $312.2 million to Meadow Partners, generating net ca | Jun 1, 2026 |
| NTLA | PRESS-RELEASE | neutral | 5/10 | Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p | Jun 1, 2026 |
| ATEX | PRESS-RELEASE | neutral | 1/10 | Anterix Inc. announced it will host a conference call on June 11 to discuss its fiscal Q4 2026 results. | Jun 1, 2026 |
| TGTX | PRESS-RELEASE | bullish | 5/10 | TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing B | Jun 1, 2026 |
| PDM | PRESS-RELEASE | bullish | 5/10 | Piedmont Realty Trust reported strong Q2 leasing activity at the NAREIT REITWeek conference: 240,000 sq ft leased so far | Jun 1, 2026 |